Dr. Baikadi studies how radiation therapy can be better managed to treat various types of cancer, with a special focus on prostate cancer and recurrent brain tumors. He compares different radiation methods to see which ones provide better results for patients while keeping their quality of life in mind. His work often involves looking at long-term effects of treatments and how patients feel about their health after receiving these therapies.
Key findings
In a study of prostate cancer treatments, only 3.3% of patients reported severe long-term side effects after a combined radiation approach over 18 months.
For recurrent brain tumors, effective dose management helped control tumor growth while protecting brain function.
From his analysis of prostate cancer patients, 80% experienced decreased sexual functioning after treatment, yet only 1% had urinary incontinence, highlighting different impacts on quality of life.
In a study of prostate cancer patients treated with brachytherapy, 15% experienced severe urinary or gastrointestinal side effects after about 8 years.
In a lung cancer study, 80% of patients showed a positive response to a combination of chemotherapy and radiotherapy, indicating its effectiveness.
Frequently asked questions
Does Dr. Baikadi study prostate cancer?
Yes, Dr. Baikadi conducts extensive research on prostate cancer, particularly focusing on radiation therapy methods and their effects.
What types of treatments has Dr. Baikadi researched?
He has researched various radiation therapies, combining them with other treatments like chemotherapy for different cancers, including prostate and lung cancer.
Is Dr. Baikadi's work relevant to patients with recurrent brain tumors?
Absolutely, his research focuses on improving radiation treatment strategies for patients with recurrent brain tumors.
What does Dr. Baikadi's research say about the side effects of cancer treatments?
His studies indicate that some combinations of radiation treatments lead to manageable side effects, although some patients may experience significant issues like sexual dysfunction.
How does Dr. Baikadi ensure treatments are safe and effective?
He evaluates the outcomes and side effects of various radiation methods in clinical trials, aiming for optimal patient care.
Publications in plain English
Dose planning management of patients undergoing salvage whole brain radiation therapy after radiosurgery.
2016
Medical dosimetry : official journal of the American Association of Medical Dosimetrists
Saw CB, Battin F, McKeague J, Haggerty M, Baikadi M +1 more
Plain English This study looked at how to effectively plan radiation treatment for patients whose brain tumors have returned after previous radiation therapy. The researchers found that by carefully managing the dose and targeting specific areas, they can help control tumor growth while still protecting patients' brain function. This is important because it offers a structured approach to treating recurrent brain tumors, which are challenging to manage with standard methods.
Who this helps: This helps patients with recurrent brain tumors and their doctors.
Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial.
2015
Cancer
Bruner DW, Hunt D, Michalski JM, Bosch WR, Galvin JM +11 more
Plain English This study compared two radiation therapy methods for treating prostate cancer: 3-dimensional conformal radiation therapy (3D-CRT) and intensity-modulated radiation therapy (IMRT). Researchers looked at how patients reported changes in bladder, bowel, and sexual function after receiving high doses of radiation. They found that there were no significant differences in these functions between the two therapy methods, even though IMRT allowed for lower doses to healthy tissues.
Who this helps: Patients undergoing treatment for prostate cancer.
Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
2012
International journal of radiation oncology, biology, physics
Lawton CA, Yan Y, Lee WR, Gillin M, Firat S +5 more
Plain English This research study looked at the long-term effects of combining external-beam radiation therapy with permanent brachytherapy in treating men with localized prostate cancer. After following 131 patients for about 8 years, they found that 15% experienced severe side effects related to their urinary or gastrointestinal health. Additionally, 42% suffered from severe impotence, and 18% had a recurrence of cancer based on specific medical definitions. This matters because while the combined treatment shows effective cancer control, it may cause more long-term side effects compared to other treatment options.
Who this helps: This helps patients with prostate cancer and their doctors in making informed treatment decisions.
Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019.
2007
Cancer
Lee WR, Bae K, Lawton C, Gillin M, Morton G +5 more
Plain English This study looked at the effects of combining two types of radiation therapy—external-beam radiotherapy and brachytherapy—on men with prostate cancer. The researchers found that after treatment, about 15% of patients experienced severe side effects affecting their urinary or digestive systems, and around 19% had a return of cancer based on one definition. This research is important because it helps doctors understand the risks associated with this treatment approach and how it compares to other methods.
Who this helps: Patients with prostate cancer undergoing this treatment.
A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019.
2006
International journal of radiation oncology, biology, physics
Lee WR, DeSilvio M, Lawton C, Gillin M, Morton G +5 more
Plain English This study looked at the side effects of a combined cancer treatment for men with moderate-risk prostate cancer. Researchers treated 138 patients with a type of radiation therapy and found that 7.6% experienced severe short-term side effects. After 18 months, only 3.3% had severe long-term side effects, which is in line with earlier studies.
Who this helps: This helps patients with prostate cancer and their doctors understand the safety of a combined treatment approach.
Quality assurance methods for the first Radiation Therapy Oncology Group permanent prostate implant protocol.
2006
Brachytherapy
Gillin MT, Dunning BF, Lawton CA, Foley WD, Byhardt RW +7 more
Plain English This study looked at how well different hospitals followed guidelines for implanting radioactive sources in prostate cancer patients. Out of 95 patients, only 89 met the required standards based on the hospitals' data, and this number dropped even further when re-evaluated by expert doctors, highlighting a major need for better oversight. Improving how these procedures are reviewed is important because it can lead to better treatment outcomes for patients.
Who this helps: This helps prostate cancer patients who are receiving radioactive implants.
A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019.
2006
Brachytherapy
Lee WR, Bae K, Lawton CA, Gillin MT, Morton G +5 more
Plain English This study looked at how effective a specific type of prostate cancer treatment was by measuring the radiation dose delivered to the prostate after the treatment. Among the 119 patients analyzed, the average dose received by 90% of the prostate was 105.6% of the target dose, while nearly 90% of the prostate received at least the full prescribed dose. These findings are important because they help establish whether the treatment procedures are consistent across different medical centers, which can improve overall patient care and outcomes.
Who this helps: This helps patients undergoing prostate cancer treatment and their doctors.
Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05.
2005
International journal of radiation oncology, biology, physics
Feigenberg SJ, Lee WR, Desilvio ML, Winter K, Pisansky TM +5 more
Plain English This study looked at the quality of life for men receiving prostate brachytherapy, a treatment for prostate cancer, over the first year. Researchers found that while 80% reported decreased sexual functioning a year after treatment, the rate of urinary incontinence was surprisingly low at just 1%. This matters because it highlights that many men experience challenges with sexual health following treatment, even as their overall quality of life remains high.
Who this helps: This information benefits patients undergoing prostate cancer treatments and their doctors.
Perineal recurrence of adenocarcinoma of prostate following radiation therapy.
1988
Urology
Thompson IM, Baikadi M, Berchmans J, Berkland M, Ortiz R
Plain English This study looked at two men who developed prostate cancer recurrence in the perineum (the area between the genitals and the anus) after receiving radiation treatment. The researchers found that the radiation dose delivered to this area was not sufficient to kill the cancer cells. This information is important because it highlights a potential risk of cancer returning in unusual locations after radiation therapy and discusses better treatment options for this problem.
Who this helps: This helps patients who have undergone radiation therapy for prostate cancer by providing insights into possible challenges they may face.
Concurrent cisplatin and etoposide with radiotherapy in locally advanced non-small cell lung cancer.
1987
Cancer treatment reports
Friess GG, Baikadi M, Harvey WH
Plain English This study focused on patients with a specific type of lung cancer and examined the effects of combining radiotherapy with two chemotherapy drugs, cisplatin and etoposide. Out of 20 patients treated, 80% showed a positive response to the therapy, and while the exact median survival time is not established, it is at least 13.5 months. This combination treatment was generally well-tolerated, with only mild side effects observed, highlighting its potential effectiveness and safety for these patients.
Who this helps: This benefits patients with locally advanced non-small cell lung cancer.
An intraoral-extraoral radiation carrier for tumors of the lip.
1984
The Journal of prosthetic dentistry
Cameron SM, Baikadi M, Janaki LM
Plain English Researchers studied a new device that helps deliver radiation therapy specifically to tumors on the lip. They created a special carrier that can be used both inside the mouth and outside the mouth, allowing for targeted treatment. This is important because it could improve the effectiveness of lip cancer treatments and minimize damage to surrounding healthy tissue.
Who this helps: This helps patients with lip tumors.